Full TitleA Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Cobimetinib in Patients with Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to find the optimal doses of two investigational drugs when given in combination in patients with locally advanced or metastatic solid tumors that continue to grow despite prior therapy. The drugs are MPDL3280A and cobimetinib.
MPDL3280A is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. MPDL3280A is given intravenously (by vein).
Cobimetinib works by inhibiting MEK, a protein which fuels cancer growth. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a locally advanced or metastatic solid tumor that has continued to grow despite standard therapy or for which no standard therapy exists.
- Three to four weeks must have passed since completion of prior therapies and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Matthew Hellmann at 646-888-4863.